SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RNAZ

Transcode Therapeutics, Inc. (NASDAQ:RNAZ)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.16-$0.14 (-10.77%)
 
Market cap
$1.23M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 8, 2021
Market Cap$1.23M-87.2%
Revenue (ttm)$0
Net Income-$145.36M-435.7%
EPS-$54.23+85.0%
Shares Out1.06M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,671
Open$1.35
Previous Close$1.30
Day's Range$1.01 - $1.35
52-Week Range$1.01 - $12.60
Beta1.27
AnalystsBuy
Price Targetn/a
Earnings DateMar 3, 2027
-10.77% (1D)
No price history available.

About RNAZ

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.

Address
6 Liberty Square, Boston, MA, 02109, US
Market Cap
1 million
Employees
12
Industrial Classification
Biotechnology
Financial Health Score
Weak
From RNAZ’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-10.77%
5 Days
-13.43%
1 Month
-32.56%
6 Months
-81.41%
1 Year
-87.18%

$RNAZ stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RNAZ holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RNAZ's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RNAZ Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RNAZ patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RNAZ from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RNAZ

VXFVanguard Extended Market ETF$10.67K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RNAZ’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.